Aflatoxin and hepatitis B virus biomarkers: A paradigm for complex environmental exposures and cancer risk

Cancer Biomarkers

Volumn 1, Issue 1, 2005, Pages 5-14

  Groopman, John D ^a   Johnson, Denise ^a   Kensler, Thomas W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; BIOLOGICAL MARKER; PROTEIN P53;

ANIMAL; BIOLOGICAL MODEL; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; LIVER CELL CARCINOMA; LIVER TUMOR; METHODOLOGY; POLLUTANT; PUBLIC HEALTH; REVIEW; RISK FACTOR; VIROLOGY;

AFLATOXINS; ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; EPIDEMIOLOGY, MOLECULAR; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; PUBLIC HEALTH; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049188036     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2005-1103     Document Type: Article

References (47)

1. J.-S. Wang, J.M. Links and J.D. Groopman, Molecular Epidemiology and Human Risk Monitoring, in: Molecular Drug Metabolism and Toxicology, OCIA International Press, London, 2000, pp. 147-166.
2. J.D. Groopman and T.W. Kensler, The light at the end of the tunnel for chemical-specific biomarkers: Daylight or headlight? Carcinogenesis 20 (1999), 1-11.
3. M.C.Kew, Epidemiology of hepatocellular carcinoma, Toxicol 181-182 (2002), 35-38.
4. Aflatoxins, IARC Monograph Evaluation Carcinogenic Risks to Humans 56 (1993), 245-395.
5. W.F.J. Busby and G.N.Wogan, Aflatoxins, in: Chemical Carcinogens, C.E. Searle, ed.,Washington D.C., American Chemical Society, 1984, pp. 945-1136.
6. R.K. Ross, J.M. Yuan, M.C. Yu, G.N. Wogan, G.S. Qian, J.T. Tu, J.D. Groopman, Y.T. Gao and B.E. Henderson, Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma, Lancet 339 (1992), 943-946.
7. G.S. Qian, R.K. Ross, M.C. Yu, J.M. Yuan, Y.T. Gao, B.E. Henderson, G.N. Wogan and J.D. Groopman, A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China, Cancer Epidemiology, Biomarkers and Prevention 3 (1994), 3-10.
8. L.Y. Wang, M. Hatch, C.J. Chen, B. Levin, S.L. You, S.N. Lu, M.H.Wu, W.P.Wu, L.W.Wang et al., Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan, International Journal of Cancer 67 (1996), 620-625.
9. M.W. Yu, J.P. Lien, Y.H. Chiu, R.M. Santella, Y.F. Liaw and C.J. Chen, Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan, Journal of Hepatology 27 (1997), 320-330.
10. T.W. Kensler, G.-S. Qian, J.-G. Chen and J.D. Groopman, Hepatocarcinogensis as a paradigm for cancer prevention, Nature Cancer Reviews 3 (2003), 321-323.
11. B.D. Roebuck, Y.-L. Liu, A.E. Rogers, J.D. Groopman and T.W. Kensler, Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz): Predictive role for short-term molecular dosimetry, Cancer Research 51 (1991), 5501-5506.
12. G. Sabbioni, P.L. Skipper, G. B̈uchi and S.R. Tannenbaum, Isolation and characterization of the major plasma albumin adduct formed by aflatoxin B1 in vivo in rats, Carcinogenesis 8 (1987), 819-824.
13. F.Z. Shaebar, J.D. Groopman, G.-S. Qian and G.N. Wogan, Quantitative analysis of aflatoxin-albumin adducts, Carcinogenesis 14 (1993), 1203-1208.
14. L.-S. Gan, P.L. Skipper, X. Peng, J.D. Groopman, J.-S. Chen, G.N. Wogan and S.R. Tannenbaum, Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: Correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1, Carcinogenesis 9 (1988), 1323-1325.
15. C.P.Wild, Y. Jiang, G. Sabbioni, B. Chapot and R. Montesano, Evaluation of methods for quantitation of aflatoxin albumin adducts and their application to human exposure assessment, Cancer Res. 50 (1990), 245-251.
16. J.D. Groopman, W.F. Busby and G.N. Wogan, The nuclear distribution of aflatoxin B1 and its interaction with histones in vivo, Cancer Research 40 (1980), 4343-4351.
17. J.M. Jez, T.G. Flynn and T.M. Penning, A new nomenclature for the aldo-keto reductase superfamily, Biochemical Pharmacology 54 (1997), 639-647.
18. L.S. Ireland, D.J. Harrison, G.E. Neal and J.D. Hayes, Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase, Biochem J. 332 (1998), 21-34.
19. L.P. Knight, T. Primiano, J.D. Groopman, T.W. Kensler and T.R. Sutter, cDNAcloning, expression, and activity of a second human aflatoxin B1-metabolising member of the aldo-keto reductase superfamily, AKR7A3, Carcinogenesis 20 (1999), 1215-1223.
20. M.K. Kwak, P.A. Egner, P.M. Dolan, M. Ramos-Gomez, J.D. Groopman, K. Itoh, M. Yamamoto and T.W. Kensler, Role of phase 2 enzyme induction in chemoprotection by dithiolethiones, Mutation Research 480-481 (2001), 305-315.
21. T. Primiano, J.A. Gastel, T.W. Kensler and T.R. Sutter, Isolation of cDNAs representing dithiolethione-responsive genes, Carcinogenesis 17 (1996), 2297-2303.
22. C. Praml, L. Savelyeva and M. Schwab, Aflatoxin B1 aldehyde reductase (AFAR) genes clusters at 1p35-1p36.1 in a region frequently altered in human tumour cells, Oncogene 22 (2003), 4765-4773.
23. M. Hollstein, D. Sidransky, B. Vogelstein and C.C. Harris, p53 mutations in human cancers, Science 253 (1991), 49-53.
24. M.S. Greenblatt, W.P. Bennett, M. Hollstein and C.C. Harris, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Research 54 (1994), 4855-4878.
25. B. Vogelstein and K.W. Kinzler, Carcinogens leave fingerprints, Nature 355 (1992), 209-210.
26. C.C. Harris, p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment, Environmental Health Perspectives 104(Suppl 3) (1996), 435-439.
27. I.C. Hsu, R.A. Metcalf, T. Sun, J.A. Welsh, N.J. Wang and C.C. Harris, Mutational hotspot in the p53 gene in human hepatocellular carcinomas, Nature 350 (1991), 427-428.
28. B. Bressac, M. Kew, J. Wands and M. Ozturk, Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa [see comments], Nature 350 (1991), 429-431.
29. C. Challen, J. Lunec, W. Warrenl, J. Collier and M.F. Bassendine, Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain, Hepatology 16(6) (1992), 1362-1366.
30. D. Sidransky and M. Hollstein, Clinical implications of the p53 gene, Annu. Rev. Med. 47 (1996), 285-301.
31. G.D., Kirk, A.-M. Camus-Randon, M. Mendy, J.J. Goedert, P. Merle, C. Trepo, C. Brechot, P. Hainaut and R. Montesano, Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma fro The Gambia, J. Natl. Cancer Inst. 92 (2000), 148-153.
32. P.E. Jackson, G.S. Qian, M.D. Friesen, Y.-R. Zhu, P.-X. Lu, J.-B. Wang, Y.-Q. Wu, T.W. Kensler, B. Vogelstein and J.D. Groopman, Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry, Cancer Research 61 (2001), 33-35.
33. P.E. Jackson, S.-Y. Kuang, J.-B. Wang, P.T. Strickland, A. Munoz, T.W. Kensler, G.-S. Qian and J.D. Groopman, Prospective detection of codon 249 mutations in p53 in plasma of hepatocellular carcinoma patients, Carcinogenesis 10 (2003), 1657-1663.
34. S.M. Lee, Hepatitis B virus infection, New England J. Med. 337 (1997), 1733-1745.
35. P. Arbuthnot and M. Kew, Hepititis B virus and hepatocellular carcinoma, Internatl. J. Experimental Pathol. 82 (2001), 77-100.
36. M. Baptista, A. Kramvis and M.C. Kew, High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers, Hepatology 29 (1999), 946-953.
37. J. Hou, G.K. Lau, J. Cheng, C.C. Cheng, K. Luo and W.F. Carman, T1762/A1764 variants of the basal core promoter of hepatitis B virus; serological and clinical correlations in Chinese patients, Liver 19 (1999), 411-417.
38. S.Y.Kuang, P.E. Jackson, J.B.Wang, P.-X. Lu, A. Munoz, G.S. Qian, T.W. Kensler and J.D. Groopman, Specific mutations of Hepatitis B virus in plasma predict liver cancer development, Proceedings National Academy of Sciences, USA 101 (2004), 3575-3580.
39. T.W. Kensler, J.D. Groopman and B.D. Roebuck, Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man, Mutat. Res. 402 (1998), 165-172.
40. P.A. Egner, S.J. Gange, P.M. Dolan, J.D. Groopman, A. Munoz and T.W. Kensler, Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz, Carcinogenesis 16(8) (1995), 1769-1773.
41. L.P. Jacobson, B.C. Zhang, Y.R. Zhu, J.B. Wang, Y. Wu, Q.N. Zhang, L.Y. Yu, G.S. Qian, S.Y. Kuang et al., Oltipraz chemoprevention trial in Qidong, People's republic of China: study design and clinical outcomes, Cancer Epidemiology, Biomarkers and Prevention 6(4) (1997), 257-265.
42. T.W. Kensler, X. He, M. Otieno, P.A. Egner, L.P. Jacobson, B. Chen, J.S. Wang, Y.R. Zhu, B.C. Zhang, J.B. Wang et al., Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers, Cancer Epidemiology, Biomarkers and Prevention 7(2) (1998), 127-134.
43. P. Egner, J.B. Wang, Y.-R. Zhu, B.-J. Zhang, Y. Wu, Q.-N. Zhang, G.-S. Qian, S.-Y. Kuang, S.J. Gange, L.P. Jacobson, K.J. Helzlsouer, G.S. Bailey, J.D. Groopman and T.W.Kensler, Cancer chemoprevention in humans: Chlorophyllin reduces aflatoxin-DNA adducts, Proceedings National Academy of Sciences, USA 98 (2001), 14601-14606.
44. Y.R. Zhu, J.G. Chen and X.Y. Huang, Hepatocellular carcinoma in Qidong County, in: Primary Liver Cancer, Z.Y. Tang, ed., Beijing: Springer Verlag, 1989, pp. 204-222.
45. Z. Yu, Primary prevention of hepatocellular carcinoma, J Gastroenterol Hepatol 10 (1995), 674-682.
46. J.G. Chen, D.M. Parkin, J.H. Lu, Q.J. Shen, B.C. Zhang and Y.R. Zhu, Screening for liver cancer: results of a randomized controlled trial in Qidong, China. J Med Screening 10 (2003), 204-209.
47. L.A. Loeb, A mutator phenotype in cancer, Cancer Research 61 (2001), 3230-3239.